Table 1. Characteristics of included studies.
| Study | Country | Published year | Study type | Follow-up (mo) | Completed/all sample size (%) | Age, y | Experimental group (n) | Control group (n) |
| Sankaridurg et al[16] | Zhongshan, China | 2010 | RCT | 12 | 201/210 (95.71) | 6-16 | MyoVision: Type I (50), Type II (60), Type III (50) | SVLs (50) |
| Kanda et al[17] | Japan | 2018 | RCT | 6, 12, 18, 24 | 203/207 (98.07) | 6-12 | MyoVision: Type III (102) | SVLs (105) |
| Bao et al[18] | Wenzhou, China | 2020 | RCT | 6, 12 | 161/170 (94.71) | 8-13 | HAL (58), SAL (57) | SVLs (55) |
| Lam et al[19] | Hong Kong, China | 2020 | RCT | 6, 12, 18, 24 | 160/183 (87.43) | 8-13 | DIMS (93) | SVLs (90) |
RCT: Randomized controlled trial; HAL: Highly aspherical lenslets; SAL: Slightly aspherical lenslets; DIMS: Defocus incorporated multiple segments; SVLs: Single vision spectacle lenses.